查找临床试验
已按「系统性硬化症」检索，对应国际通用词 systemic sclerosis
共找到 49 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 00:25，每 5 分钟自动同步A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
China
年龄 18 Years – 65 Years
China Immunotech (Beijing) Biotechnology Co., Ltd.
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Peking University People's Hospital
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Beijing GoBroad Hospital
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
China
年龄 18 Years – 不限
Institute of Hematology & Blood Diseases Hospital, China
Safety Study of CC312 in Autoimmune Disease Patients
China
年龄 18 Years – 不限
CytoCares Inc
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
China
年龄 18 Years – 65 Years
China Immunotech (Beijing) Biotechnology Co., Ltd.
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
China
年龄 18 Years – 80 Years
Peking University Third Hospital
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 5 Years – 80 Years
AstraZeneca
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
China
年龄 18 Years – 不限
Anhui Provincial Hospital
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
China
年龄 18 Years – 不限
Antengene Biologics Limited
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Therorna
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
China
年龄 18 Years – 70 Years
Nanjing Bioheng Biotech Co., Ltd.